|View printer-friendly version|
|September 20, 2010 3:55 p.m.|
|Oral Laquinimod Demonstrated Sustained Efficacy and Safety in Patients with Multiple Sclerosis|
- Positive benefit-risk profile of laquinimod sustained in Phase II extension study Jerusalem, Israel, September 20, 2010 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced results from a 36-week active extension study evaluating two doses of laquinimod, an investigational, once-daily oral immunomodulator, for the treatment of relapsing remitting multiple sclerosis (RRMS). The double-blind, multinational study demonstrated the sustained positive benefit-risk profile of laquinimod, which was shown to reduce Gd-enhancing (GdE) T1 lesions, while maintaining a good safety profile. These findings were published online by the journal Multiple Sclerosis.